Casciati A, Taddei A, Rampazzo E, Persano L, Viola G, Cani A
Int J Mol Sci. 2024; 25(4).
PMID: 38396911
PMC: 10889160.
DOI: 10.3390/ijms25042233.
Zhang W, Oh J, Zhang W, Rathi S, Le J, Talele S
Pharm Res. 2023; 40(11):2731-2746.
PMID: 37589827
PMC: 10841221.
DOI: 10.1007/s11095-023-03574-1.
Majchrzak-Celinska A, Sidhu A, Miechowicz I, Nowak W, Barciszewska A
J Clin Med. 2022; 11(19).
PMID: 36233525
PMC: 9571128.
DOI: 10.3390/jcm11195655.
Mirzaei T, Sheikholeslami S, Bereimipour A, Jalili A, Zali A, Sharbati S
J Family Med Prim Care. 2022; 11(6):2856-2864.
PMID: 36119333
PMC: 9480797.
DOI: 10.4103/jfmpc.jfmpc_1436_21.
Bisht S, Nigam M, Kunjwal S, Sergey P, Mishra A, Sharifi-Rad J
Stem Cells Int. 2022; 2022:9653244.
PMID: 35800881
PMC: 9256444.
DOI: 10.1155/2022/9653244.
Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer.
Lee W, Frank T
Cancer Drug Resist. 2022; 4(2):424-452.
PMID: 35582031
PMC: 9019277.
DOI: 10.20517/cdr.2020.114.
Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence.
Bakhshinyan D, Adile A, Liu J, Gwynne W, Suk Y, Custers S
Sci Adv. 2021; 7(50):eabi5568.
PMID: 34878832
PMC: 8654291.
DOI: 10.1126/sciadv.abi5568.
The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis.
Shadbad M, Hosseinkhani N, Asadzadeh Z, Brunetti O, Silvestris N, Baradaran B
Front Oncol. 2021; 11:722833.
PMID: 34540691
PMC: 8445366.
DOI: 10.3389/fonc.2021.722833.
A novel synthetic microtubule inhibitor exerts antiproliferative effects in multidrug resistant cancer cells and cancer stem cells.
Park M, Hwang J, Cho Y, Kim S, Han S, Yu J
Sci Rep. 2021; 11(1):10822.
PMID: 34031528
PMC: 8144389.
DOI: 10.1038/s41598-021-90337-w.
Targeting Glioma Stem Cells.
Muftuoglu Y, Pajonk F
Neurosurg Clin N Am. 2021; 32(2):283-289.
PMID: 33781508
PMC: 8010221.
DOI: 10.1016/j.nec.2021.01.002.
Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives.
Alves A, Gomes I, Carloni A, Rosa M, da Silva L, Evangelista A
Stem Cell Res Ther. 2021; 12(1):206.
PMID: 33762015
PMC: 7992331.
DOI: 10.1186/s13287-021-02231-x.
Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress.
Olivier C, Oliver L, Lalier L, Vallette F
Front Mol Biosci. 2021; 7:620677.
PMID: 33585565
PMC: 7873048.
DOI: 10.3389/fmolb.2020.620677.
The Great Escape: The Power of Cancer Stem Cells to Evade Programmed Cell Death.
Castelli V, Giordano A, Benedetti E, Giansanti F, Quintiliani M, Cimini A
Cancers (Basel). 2021; 13(2).
PMID: 33477367
PMC: 7830655.
DOI: 10.3390/cancers13020328.
Oncogenic Ras downregulates expression through generation of reactive oxygen species.
Jun S, Kim S, Kim B, Chang I, Park S
Korean J Physiol Pharmacol. 2020; 24(3):267-276.
PMID: 32392918
PMC: 7193907.
DOI: 10.4196/kjpp.2020.24.3.267.
Characterization of Ablation Thresholds for 3D-Cultured Patient-Derived Glioma Stem Cells in Response to High-Frequency Irreversible Electroporation.
Ivey J, Wasson E, Alinezhadbalalami N, Kanitkar A, Debinski W, Sheng Z
Research (Wash D C). 2019; 2019:8081315.
PMID: 31549086
PMC: 6750069.
DOI: 10.34133/2019/8081315.
MDR1 in immunity: friend or foe?.
Bossennec M, Di Roio A, Caux C, Menetrier-Caux C
Oncoimmunology. 2018; 7(12):e1499388.
PMID: 30524890
PMC: 6279327.
DOI: 10.1080/2162402X.2018.1499388.
SOX2 in cancer stemness: tumor malignancy and therapeutic potentials.
Mamun M, Mannoor K, Cao J, Qadri F, Song X
J Mol Cell Biol. 2018; 12(2):85-98.
PMID: 30517668
PMC: 7109607.
DOI: 10.1093/jmcb/mjy080.
Natural products: a hope for glioblastoma patients.
Vengoji R, Macha M, Batra S, Shonka N
Oncotarget. 2018; 9(31):22194-22219.
PMID: 29774132
PMC: 5955138.
DOI: 10.18632/oncotarget.25175.
Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats.
Chu T, Chan H, Hu T, Wang E, Ma Y, Huang S
Cancer Med. 2018; 7(6):2567-2580.
PMID: 29683262
PMC: 6010827.
DOI: 10.1002/cam4.1487.
'Et tu, inhibitor?': the potential for HIV inhibitors to prime P-gp-mediated chemoresistance in cancer.
Shull A, Farrell C
Future Sci OA. 2018; 4(2):FSO269.
PMID: 29379643
PMC: 5778385.
DOI: 10.4155/fsoa-2017-0134.